fda advisory_committee_meeting
saveAstraZeneca Plc — camizestrant (FDA Advisory Committee Meeting)
community read0 votes
Therapy area: Oncology. Indication: Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)
Therapy area: Oncology. Indication: Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)